|  |  |
| --- | --- |
| MinutesDrug Utilization Review Board MeetingDATE: September 11, 2024 |  |



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting

Meeting opened at 6:00 p.m. by Laura Spring, MD

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Sarah M McGee, MD; Laura Spring, MD; Rebekah Rice, RPh, CDCES; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:**

**Agenda Items:**

* Welcome and Introductory Remarks
* Guest Speaker
* Minutes
* Pipeline Update
* Annual Special Populations Update
* RSV Quality Assurance Analysis and Seasonal Update
* Respiratory Agents, Inhaled Quality Assurance Analysis
* MHDL Update
* **DUR Operational Update**
* **MassHealth Update**
* **Hypnotics Quality Assurance Analysis**
* **Open Forum**

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow Up** |
| **Guest Speakers** | * Daniel Bassoff, Medical Knowledge Care Team at Sarepta Therapeutics, spoke on Elevidys.
 | **Follow Up**Informational/Advisory |

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| **Minutes** | Motion to approve the minutes for June 2024 was made by Timothy Fensky, RPh and was seconded by Sarah M McGee, MD. | **Follow-up**Minutes are approved. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| Pipeline Update | Pipeline Update by Dr. Katelyn MeyerThis Pipeline Update provided a brief overview of clinical and regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.  | **Follow-up**Informational/Advisory |
| Action | Discussion* Overview of Investigational Agents giroctocogene fitelparvovec and UX111
* Discussion of Potential Impact of the Agents

Conclusions* If approved, giroctocogene fitelparvovec would become the second gene therapy approved for hemophilia A, joining Roctavian® (valcotogogene roxaparvovec).
* If approved, UX111 would become the first and only FDA-approved therapy for Mucopolysaccharidosis (MPS) IIIA.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Annual Special Populations Update** | Annual Special Populations Update by Dr. Bhakti Patel and Dr. Kaelyn BossThis overview was a summary of the current structure of the Drug Utilization Review Special Populations Program. It summarized clinical outcomes of the program over the past year.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Provided annual overview of the MassHealth Special Populations Program
* Reviewed financial and clinical outcomes of pharmacist interventions
* Outlined the Prior Authorization (PA) Recertification Outreach Program

Conclusions/Recommendations* The Special Populations Program encourages collaboration among MassHealth programs to improve member outcomes.
* Outcomes suggest that the MassHealth Special Populations Program has a positive clinical impact on MassHealth members and potential cost savings for MassHealth.
* Plan to continue evaluation of the MassHealth Special Populations program to identify opportunities to expand services and evaluate outcomes.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Respiratory Syncytial Virus (RSV) Quality Assurance (QA) Analysis and Seasonal Update** | RSV Quality Assurance Analysis and Seasonal Update by Dr. Warren SmithThis overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed the latest prophylactic options available for the prevention of RSV
* Examined MassHealth utilization for the RSV prophylactic agents
* Discussed American Academy of Pediatrics (AAP) and Advisory Committee on Immunization Practices (ACIP) recommendations
* Provided an overview of the RSV pipeline

Conclusions/Recommendations* There are now multiple agents to prevent RSV lower respiratory tract disease (LRTD) in infants (Beyfortus®, Synagis®, maternal immunization with Abrysvo®).
* For the 2024-2025 RSV season, PA criteria for Synagis® will require a step-through of Beyfortus®; Beyfortus® will be available without PA for members <8 months and PA will be required for members between 8 and 19 months.
* Abrysvo®, Arexvy®, and mResvia® are available for adults ≥60 years of age (one of which, Arexvy®, is approved for patients ≥50 years of age).
	+ PA will be required for members outside of the above patient populations.
	+ ACIP recommendations for RSV vaccines include vaccination for patients 60 to 74 years of age who are at increased risk and all patients ≥75 years of age.
* The pipeline includes investigational agents, such as Clesrovimab, which have the potential to impact the RSV prophylactic landscape in infants even further.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Inhaled Respiratory Agents** | Inhaled Respiratory Agents by Dr. Karen Stevens This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Provided an overview of asthma and chronic obstructive pulmonary disease (COPD) treatment
* Described current MassHealth management for inhaled respiratory agents
* Presented current MassHealth utilization and PA summaries
* Reviewed subanalyses of short-acting beta-agonist (SABA) utilization, product discontinuations, and pipeline
* Discussed recommendations following QA analysis

Conclusions/Recommendations* Effective November 12, 2024, remove PA from Asmanex® Twisthaler to allow access to additional inhaled corticosteroid (ICS) inhaler, given shortages of Asmanex® HFA.
* Symbicort® will be listed with PD designation effective November 12, 2024.
* Future SABA analysis will include subgroups of interest (e.g., diagnosis, age, TPL, etc.).
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Drug List (MHDL) Update** | MHDL Update by Dr. Chris NelsonMHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout. | **Follow-up**Informational/Advisory |
| Action | Discussion * Effective October 1, 2024:
	+ There were 16 additions the MHDL Drug list.
	+ There were 17 changes in PA status.
* There were several changes to Coverage Status for Medical Billing, Brand Name Preferred Over Generic List; 90-day Initiative; and Updates and Changes to the MHDL.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **DUR Operational Update** | DUR Operational Update by Dr. Kristen DanisDUR operational overview included statistics associated with PA review and PA response, and call center metrics. | **Follow-up**Informational/Advisory |
| Action | Discussion * Operational statistics, including PA and call center metrics up to December 31, 2024, were discussed
* All metrics met or exceeded service level agreements.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Update** | MassHealth Update by Dr. Kimberly LenzMassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed current clinical program initiatives
* Provided direct negotiation status update
* Discussed operational updates
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Hypnotics Quality Assurance Analysis** | Oncology Immunotherapy Quality Assurance Analysis by Dr. Amy DionneThis overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * This presentation was tabled until the next DUR Board meeting.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Open Forum** | Open Forum | **Follow-up**Informational/Advisory |
| Action | Discussion * This presentation was tabled until the next DUR Board meeting.
 | **Conclusion**N/A |

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_